Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896126 · ClinicalTrials.gov registry record
GI-Challenge Study for Gastroparesis Patients and Healthy Controls
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 43
- Enrollment target
NCT03896126: Clinical Trial study, sponsored by Stanford University.
NCT03896126 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03896126 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Gastroparesis Patients and Healthy Controls ages 20-49 will be asked to participate in an observational study measuring vagal activity following food ingestion in order to establish parameters of autonomic nerve/vagal function in healthy human subjects compared to those with gastroparesis. Information generated from this study may be used in the future to establish what is normal and abnormal enteric vagal tone and how much vagal nerve stimulation treatment may be required to help patients with gastroparesis.
Primary Outcome
The ANSAR computes sympathovagal score by collecting sympathetic low frequency area (LFa) and parasympathetic respiratory frequency area (RFa) data (both measured as beats per minute squared, or BPM2) and calculating the ratio of these two complementary measures of the autonomic nervous system (LFa/RFa) to arrive at one aggregated score.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2025-08-18 |
Why NCT03896126 stopped before completion
NCT03896126 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT03896126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03896126 about?
NCT03896126 is a clinical study titled "GI-Challenge Study for Gastroparesis Patients and Healthy Controls". Gastroparesis Patients and Healthy Controls ages 20-49 will be asked to participate in an observational study measuring vagal activity following food ingestion in order to establish parameters of autonomic nerve/vagal function in healthy human subjects compared to those with gastroparesis. Informati...
What is the current status of trial NCT03896126?
This trial is currently terminated. The enrollment target is 43 participants. The study started on 2019-01-01. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT03896126?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT03896126?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI